guest ::
| Home > Publications database > Metabolically-Defined Body Size Phenotypes and Risk of Endometrial Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). > print |
| Home > Publications database > Metabolically-Defined Body Size Phenotypes and Risk of Endometrial Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). > print |
| 001 | 179587 | ||
| 005 | 20240229145548.0 | ||
| 024 | 7 | _ | |a 10.1158/1055-9965.EPI-22-0160 |2 doi |
| 024 | 7 | _ | |a pmid:35437568 |2 pmid |
| 024 | 7 | _ | |a 1055-9965 |2 ISSN |
| 024 | 7 | _ | |a 1538-7755 |2 ISSN |
| 024 | 7 | _ | |a altmetric:126954953 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2022-00765 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kliemann, Nathalie |0 0000-0002-1778-9998 |b 0 |
| 245 | _ | _ | |a Metabolically-Defined Body Size Phenotypes and Risk of Endometrial Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). |
| 260 | _ | _ | |a Philadelphia, Pa. |c 2022 |b AACR |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1656677942_3320 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2022 Jul 1;31(7):1359-1367 |
| 520 | _ | _ | |a Obesity is a risk factor for endometrial cancer but whether metabolic dysfunction is associated with endometrial cancer independent of body size is not known.The association of metabolically-defined body size phenotypes with endometrial cancer risk was investigated in a nested case-control study (817 cases/ 817 controls) within the European Prospective Investigation into Cancer and Nutrition (EPIC). Concentrations of C-peptide were used to define metabolically healthy (MH; <1st tertile) and metabolically unhealthy (MU; >=1st tertile) status among the control participants. These metabolic health definitions were combined with normal weight (NW; Body Mass Index (BMI)<25kg/m2 or Waist Circumference (WC)<80cm or Waist-to-Hip Ratio (WHR)<0.8) and overweight (OW; BMI>=25kg/m2 or WC>=80cm or WHR>=0.8) status, generating four phenotype groups for each anthropometric measure: (1)MH/NW, (2)MH/OW (3)MU/NW and (4)MU/OW.In a multivariable-adjusted conditional logistic regression model, compared with MH/NW individuals, endometrial cancer risk was higher among those classified as MU/NW (OR/WC=1.48; 95%CI 1.05-2.10 and OR/WHR=1.68; 95%CI 1.21-2.35) and MU/OW (OR/BMI=2.38, 95%CI 1.73-3.27; OR/WC=2.69, 95%CI 1.92-3.77 and OR/WHR=1.83, 95%CI 1.32-2.54). MH/OW individuals were also at increased endometrial cancer risk compared to MH/NW individuals (OR/WC=1.94, 95%CI 1.24-3.04).Women with metabolic dysfunction appear to have higher risk of endometrial cancer regardless of their body size. However, overweight status raises endometrial cancer risk even among women with lower insulin levels, suggesting that obesity-related pathways are relevant for the development of this cancer beyond insulin.Classifying women by metabolic health may be of greater utility in identifying those at higher risk for endometrial cancer than anthropometry per se. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Ould Ammar, Romain |0 0000-0003-4801-3401 |b 1 |
| 700 | 1 | _ | |a Biessy, Carine |0 0000-0003-3950-0929 |b 2 |
| 700 | 1 | _ | |a Gicquiau, Audrey |b 3 |
| 700 | 1 | _ | |a Katzke, Verena |0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |b 4 |u dkfz |
| 700 | 1 | _ | |a Kaaks, Rudolf |0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |b 5 |u dkfz |
| 700 | 1 | _ | |a Tjoenneland, Anne |b 6 |
| 700 | 1 | _ | |a Olsen, Anja |0 0000-0003-4788-503X |b 7 |
| 700 | 1 | _ | |a Sánchez, Maria-Jose |0 0000-0003-4817-0757 |b 8 |
| 700 | 1 | _ | |a Crous-Bou, Marta |b 9 |
| 700 | 1 | _ | |a Pasanisi, Fabrizio |b 10 |
| 700 | 1 | _ | |a Tin Tin, Sandar |b 11 |
| 700 | 1 | _ | |a Perez-Cornago, Aurora |0 0000-0002-5652-356X |b 12 |
| 700 | 1 | _ | |a Aune, Dagfinn |0 0000-0002-4533-1722 |b 13 |
| 700 | 1 | _ | |a Christakoudi, Sofia |b 14 |
| 700 | 1 | _ | |a Heath, Alicia K |0 0000-0001-6517-1300 |b 15 |
| 700 | 1 | _ | |a Colorado-Yohar, Sandra M |b 16 |
| 700 | 1 | _ | |a Grioni, Sara |0 0000-0002-5891-8426 |b 17 |
| 700 | 1 | _ | |a Skeie, Guri |0 0000-0003-2476-4251 |b 18 |
| 700 | 1 | _ | |a Sartor, Hanna |0 0000-0002-1116-5199 |b 19 |
| 700 | 1 | _ | |a Idahl, Annika |0 0000-0002-7865-4560 |b 20 |
| 700 | 1 | _ | |a Rylander, Charlotta |b 21 |
| 700 | 1 | _ | |a M May, Anne |b 22 |
| 700 | 1 | _ | |a Weiderpass, Elisabete |0 0000-0003-2237-0128 |b 23 |
| 700 | 1 | _ | |a Freisling, Heinz |0 0000-0001-8648-4998 |b 24 |
| 700 | 1 | _ | |a Playdon, Mary C |0 0000-0001-6082-0447 |b 25 |
| 700 | 1 | _ | |a Rinaldi, Sabina |b 26 |
| 700 | 1 | _ | |a Murphy, Neil |b 27 |
| 700 | 1 | _ | |a Huybrechts, Inge |0 0000-0003-3838-855X |b 28 |
| 700 | 1 | _ | |a Dossus, Laure |0 0000-0003-2716-5748 |b 29 |
| 700 | 1 | _ | |a Gunter, Marc J |0 0000-0001-5472-6761 |b 30 |
| 773 | _ | _ | |a 10.1158/1055-9965.EPI-22-0160 |g p. cebp.EPI-22-0160-A.2022 |0 PERI:(DE-600)2036781-8 |n 7 |p 1359-1367 |t Cancer epidemiology, biomarkers & prevention |v 31 |y 2022 |x 1055-9965 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:179587 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-02-02 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-02-02 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-10 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER EPIDEM BIOMAR : 2021 |d 2022-11-10 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-10 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-10 |
| 920 | 1 | _ | |0 I:(DE-He78)C020-20160331 |k C020 |l C020 Epidemiologie von Krebs |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C020-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|